• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Hygienic Packaging Technology

    Trends in Solid Oral Dosage Delivery

    5 Reasons Paper Has No Place in Contract Manufacturing

    Injectable Drug Delivery Trends

    Pharmaceutical Manufacturing Equipment Trends
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    AGC Biologics Expands Cell and Gene Facility in Italy

    Celonic to Boost Cell & Gene Therapy Production

    Pharmaron Acquires Biomanufacturing Site in the UK from AbbVie

    Aptamer Extends Collaboration with AstraZeneca

    Fujifilm Breaks Ground on Major Expansion of Biologics Facility in Denmark
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    AGC Biologics Expands Cell and Gene Facility in Italy

    Celonic to Boost Cell & Gene Therapy Production

    Pharmaron Acquires Biomanufacturing Site in the UK from AbbVie

    Fujifilm Breaks Ground on Major Expansion of Biologics Facility in Denmark

    Reed-Lane Facility Virtual Tour
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Reed-Lane Facility Virtual Tour

    Hygienic Packaging Technology

    Reshaping the Pharmaceutical Supply Chain

    Serialization: Level 5 Solution

    Covectra Introduces Next-Gen Serialization Solution
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Data Management Trends

    AGC Biologics Expands Cell and Gene Facility in Italy

    Celonic to Boost Cell & Gene Therapy Production

    Pharmaron Acquires Biomanufacturing Site in the UK from AbbVie

    Aptamer Extends Collaboration with AstraZeneca
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Guide to Maintaining Validation of Older Facilities: Why, When and How

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Top BioPharma Form Accumulus Synergy

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Baxter BioPharma Solutions

    PCI Pharma Services

    Reed-Lane

    Aphena Pharma Solutions

    Cytovance Biologics
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Alcami

    Reed-Lane

    Almac Group

    Aphena Pharma Solutions

    Baxter BioPharma Solutions
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    Newsmakers Interview: Peter Soelkner

    A conversation with the managing director of Vetter Pharma International GmbH

    Related CONTENT
    • Vetter continues to implement its long-term sustainability strategy
    • Vetter continues its long-term investment strategy to sustain future growth
    • Vetio Animal Health
    • Contracting And Outsourcing Exhibitor List
    • Hovione Starts Phase 1 Clinical Trial of HY02
    Gil Y. Roth04.05.10

    Newsmakers Interview: Peter Soelkner



    A conversation with the managing director of Vetter Pharma International GmbH



    By Gil Y. Roth



    In November 2009, Vetter Pharma International announced that it was launching Vetter Development Service with a new facility in Skokie, IL. To find out more about the German company’s new foothold in the U.S., as well as further expansion plans and perspectives on branded vs. generic injectable manufacturing, I spoke with VPI’s managing director, Peter Soelkner, who will head up the new initiative.

    Contract Pharma: What was the impetus for Vetter Development Service and the new site?

    Peter Soelkner: We are in the business of manufacturing and producing prefilled injection systems and a full array of primary packaging materials, specifically single- and dual-chamber syringes, and cartridges and vials. We stand out with our expertise and high quality in manufacturing compounds with little API or substance loss. With our Key Account Management concept, we work with clients from early development all the way through commercial manufacturing. So, in order to focus more on development, we began a strategy at the end of 2008 to expand our capacity through Vetter Development Service. This resulted in the new Chicago site.

    CP: Why did you choose Chicago?


    Peter Soelkner of Vetter Pharma International

    PS: Chicago definitely has several advantages. It’s an international hub, reachable by almost every major airport in the U.S., Europe, and other parts of the world. The Illinois Science + Technology Park is just 30 minutes away from O’Hare, 20 minutes from downtown Chicago, and 20 minutes from Chicago´s main lifescience community, with direct train access. It’s in-between for both east coast and west coast clients, and in the midwestern region, there’s a cluster of pharma and biotech companies. Within an hour’s drive, there’s a workforce potential of 70,000 to 80,000 people who are currently working in the pharma, biotech or biomedical industries. Baxter, Abbott, Hospira, Takeda and Astellas are working in that locale. I don’t have to explain to a client why we’re there.

    It’s “only seven hours away” from central Europe, as opposed to the west coast, where I’m located right now, which is nine hours. That gives you more time in the work day to synchronize while offices are open.

    We definitely want to be closer to our customers. Half of our client base is already coming from North America, especially the U.S., so there’s definitely a need to be closer to that marketplace. Two-thirds of Phase I and Phase II projects are coming from the U.S. We hope that by operating in the same time zone, we can speed up the time to market. It boils down to a partnership approach, to having a good handle on project management, that you have your i’s dotted and your t’s crossed.

    This is particularly true when you work with an emerging biotech company. Frequently, they will have a great vision of their molecule and its effect on a new indication, but not necessarily the knowledge of how to bring a product to a primary packaging container that will fulfill all the regulatory requirements of international agencies.

    The new site will help further internationalize our company, enabling us to attract more talent from an international market, and not just around Lake Constance. The Illinois Science + Technology Park where the new center will be located is in close cooperation with Northwestern University, and there are other major academic institutes (six medical schools) nearby (including University of Illinois-Chicago, Rush, and University of Chicago).

    CP: How much will the Development Center cost?

    PS: We’re projecting $15 million, not including project management work.

    CP: What’s the composition of the workforce? How many staffers are coming over from Germany?

    PS: We’re bringing 15 full-time-equivalents coming over from Germany. Seven or eight of those positions will be permanent, while others will have project assignments. We’re looking to hire 10 to 15 local individuals. We picture approximately 25 heads in place by the end of the year. Once the site is really up and running, we could entertain a second shift. The site can accommodate 50 to 60 employees. Most of those will be highly qualified staff.

    CP: Are you going to show off the new digs at BIO in May?

    PS: We hope to! The lab space is already operating and the cleanroom infrastructure will be completed by early May. Long-lead items like our filling equipment will be in around summer and be operational by beginning of Q4 2010. Still, we plan to show the place off during BIO.

    There was a takeoff event on Dec. 1, 2009. It wasn’t exactly an inauguration, since some of the cleanroom suites and laboratories are under construction. The filling machine we’re bringing in from Bosch offers great advantage in disposable components, extremely low yield losses, and more, but it won’t be in the building until around May 2010. It’ll then need to be validated and qualified within the cleanroom suite.

    CP: When are you bringing clients in?

    PS: From summer onward. We plan to ramp up project work in the second half of this year, to familiarize clients with our work. And if someone is interested and needs a project done yesterday, we can certainly talk to them about accomplishing their goals with our existing services.

    We’ll be fully operational by the end of the year. In the meantime, our microbiology lab is up and running, as is the chemical analytical lab. There are around 24,000 sq. ft. for the technical disciplines. It’s not a whole factory, but with three filling rooms, it definitely covers all the tasks one needs to handle projects in early clinical phases.

    CP: What’s the site’s history?

    PS: The new site, which dates back to 1941, is a legacy facility from Pfizer (through a series of acquisitions and mergers): it was first a Searle R&D campus, then a Pharmacia R&D site, then a Pharmacia site, and then it was closed down by Pfizer at the end of 2003. It was later bought by Forest City Science + Technology Group, which has a big retail real estate presence. Forest City decided that it would get into this area to diversify from retail malls with “life science malls.” The park currently has 18 companies and almost 1,000 people on campus including such companies as the Astellas Research Institute of the Americas. Forest City has four other bioscience parks in the U.S.

    This building used to be Pharmacia’s clinical manufacturing site for parenterals, so there was some cGMP thought that went into the site’s design. It was revamped in 2001 and ‘02, and was still manufacturing in 2003. So the basic structure needed a minimum of work, outside of the WFI system, which hadn’t been operated in five years.

    At the Science + Technology Park, the floor plan and the infrastructure were ideally suited for our needs. We had to revamp the HVAC and WFI, but it’s a huge advantage for the layout of the rooms — in terms of the size of the suites and the material flow of the place — is geared toward this kind of operation. The city of Skokie and the state of Illinois have been very supportive in helping us along the way.

    CP: Does the same rationale for launching development in the U.S. hold up for commercial work? That is, would commercial clients need the same level of “hand-holding” that characterizes early-stage work?

    PS: I don’t feel that it is, from my experience. Vetter is already working with 19 of the top 20 big pharma and biotech companies, and those commercial needs are taken care of at our three sites in Germany. In Lake Constance, we have a safe environment, politically and economically speaking, with no exposure to earthquakes, hurricanes and tornadoes.

    Since a commercial injectable tends to get launched in North America and the EU, it’s going to get shipped regardless, so there’s less of an imperative for local geographic reach. With development work, there’s revamping and other changes that require that sort of flexibility, but with commercial work, it’s about consistency in reaching millions of vials with the same precision. So we’re presently covered by our existing commercial facilities in Germany.

    CP: How about Asia? Do you have expansion plans in that region?

    PS: We’re working on an Asia strategy this year, but we haven’t settled on specific countries and objectives in that region. We know we cannot neglect Asia in the next five or 10 years, and that Vetter must become a truly global company with a presence there. Chicago was our first ex-Europe expansion, and we may look at other moves, including Asia.

    CP: What are the drivers for Asia? Market access? Labor savings?

    PS: Vaccines are certainly growing in importance in the emerging regions, and other medicines are also gaining share. Operations in Asia would be more centered on regional access and distribution for clients’ products than for labor savings. Clean room operations are all about removing people from the area, to reduce contamination risks, so Asian facilities would not represent any great cost savings in terms of labor.

    For example, in our Ravensburg South site, we’re in the process of bringing on line a third clean room with a line that can handle more than 36,000 syringes an hour (north of half a million syringes a day), yet it can be operated by three individuals. So the contribution of labor costs to that equation isn’t as important as quality, since the economies of scale rise with automation.

    With labor-intensive analytical work — extractable/leachable or stability studies, for example — perhaps the equation would be different.

    CP: How does a deal like Pfizer/Aurobindo, in which Pfizer will sell generic injectables in the U.S. market, affect Vetter? Is that perceived as a new field for you to enter?

    PS: Vetter always focuses on new and innovative drugs; that is our major direction. However, the market has shifted in the last two or three years. Some big pharma companies wouldn’t touch generics and biosimilars with a 10-foot pole five years ago, but that’s all changed thanks to pipeline failures and financial pressure. The net result is that we all talk about generics and biosimilars now. With the potential for U.S. healthcare reform and everything else that’s going on in the U.S. and EU, then we have to evaluate these opportunities on a case-by-case basis. We don’t want to cherry-pick from clients’ pipelines; if we want to be a partner, we handle the latest and greatest projects from development and if they are pursuing something like biosimilars, then we look to add innovation and value to that. In those terms, we’d be talking about more patient-convenient delivery devices, for example. Being a partner means being there for all their needs. We have to react to the changed circumstances within the pharmaceutical market.

    Gil Y. Roth has been the editor of Contract Pharma since its debut in 1999. He can be reached at gil@rodpub.com.
    Related Searches
    • Manufacturing
    • pharma companies
    • contract pharma
    • API
    Suggested For You
    Vetter continues to implement its long-term sustainability strategy Vetter continues to implement its long-term sustainability strategy
    Vetter continues its long-term investment strategy to sustain future growth Vetter continues its long-term investment strategy to sustain future growth
    Vetio Animal Health Vetio Animal Health
    Contracting And Outsourcing Exhibitor List Contracting And Outsourcing Exhibitor List
    Hovione Starts Phase 1 Clinical Trial of HY02 Hovione Starts Phase 1 Clinical Trial of HY02
    Leveraging Next-Gen FSP Models to Better Manage Post-approval Regulatory Workloads Leveraging Next-Gen FSP Models to Better Manage Post-approval Regulatory Workloads
    Samsung Bioepis Obtains First Drug Approval in the U.S. Samsung Bioepis Obtains First Drug Approval in the U.S.
    Sucampo Acquires Vtesse for $200mn Sucampo Acquires Vtesse for $200mn
    Innovative Manufacturing Technology for Aseptic Filling Innovative Manufacturing Technology for Aseptic Filling
    China FDA Accepts JHL China FDA Accepts JHL's First Clinical Trial Application
    Newsmakers: Peter Soelkner Newsmakers: Peter Soelkner
    Vetter Vetter's Ravensburg Ops Underway
    Vetter Pharma International Vetter Pharma International
    Vetter Data Processing Center Gains Certification Vetter Data Processing Center Gains Certification
    Developing a Lyophilized Drug Product? Don’t Forget the Diluent Developing a Lyophilized Drug Product? Don’t Forget the Diluent

    Related Features

    • Biologics, Proteins, Vaccines | Biosimilars | Drug Development
      Biopharma Contract Manufacturing: Robust Growth Ahead

      Biopharma Contract Manufacturing: Robust Growth Ahead

      The biopharmaceutical contract manufacturing market is projected to reach $6.3 billion in 2020, and it will continue to grow over the next five years.
      William Downey, HighTech Business Decisions 11.17.20

    • Biosimilars
      Biosimilar Manufacturing Strategies

      Biosimilar Manufacturing Strategies

      Five steps to competing in a post-patent expiry era.
      George I’ons, Owen Mumford Pharmaceutical Services 09.09.20

    • Biosimilars
      The U.S. Biosimilars Market: Shaking the “Laggard” Label

      The U.S. Biosimilars Market: Shaking the “Laggard” Label

      Biosimilar uptake set to reshape the U.S. market
      Katya Svoboda and Bob Swann, ICON 05.05.20


    • Biologics, Proteins, Vaccines | Biosimilars
      Biopharma Over 20 Years

      Biopharma Over 20 Years

      A look at the key trends that have impacted the biopharma industry over the years.
      K. John Morrow, Jr. and Eric S. Langer, BioPlan Associates 11.20.19

    • Biologics, Proteins, Vaccines | Biosimilars
      Are Biotech Companies Strong Investments?

      Are Biotech Companies Strong Investments?

      Biotech capital raised via IPO has increased dramatically over the past couple of years.
      Jason Monteleone , CEO, Clinipace 05.07.19

    • Biosimilars
      Biosimilar  Market Trends

      Biosimilar Market Trends

      2017 was a record year for biosimilar approvals.
      Fiona Greer and Bruno Speder, SGS 09.11.18


    • Biologics, Proteins, Vaccines | Biosimilars | Drug Development
      Haste Makes Waste

      Haste Makes Waste

      When to sprint and when to breathe in the race from lab to clinic.
      Christian Cattaruzza, MilliporeSigma 09.11.18

    • Biologics, Proteins, Vaccines | Biosimilars
      Biopharma Manufacturing Markets

      Biopharma Manufacturing Markets

      Biomanufacturing contract services and supplies markets continue to expand
      Ronald A. Rader and Eric S. Langer, BioPlan Associates 05.08.18

    • Biologics, Proteins, Vaccines | Biosimilars
      Contract BioManufacturing in China: Creating a New Segment

      Contract BioManufacturing in China: Creating a New Segment

      An up-close look at China’s growing market for CMO services.
      Vicky Qing Xia and Leo Cai Yang, BioPlan Associates 04.10.18


    • Biologics, Proteins, Vaccines | Biosimilars | cGMP Manufacture
      Biopharmaceutical Contract Manufacturing Market

      Biopharmaceutical Contract Manufacturing Market

      The market continues to grow, projected to exceed $4 billion in 2017
      William Downey, President, HighTech Business Decisions 06.06.17

    • Aseptic Processing | Biosimilars | Drug Delivery | Logistics | Supply Chain
      Improving Packaging Processes to Meet Regulatory and Patient Needs

      Improving Packaging Processes to Meet Regulatory and Patient Needs

      The rise of advanced automation and packaging technologies
      06.02.16

    • Biosimilars | Drug Delivery | Injectables | Parenterals | Serialization | Supply Chain | Vials
      Contract Packaging Market Trends

      Contract Packaging Market Trends

      Contract packagers talk about hot growth areas and the looming 2017 DSCSA deadline
      Tim Wright, Editor 06.02.16


    • Biosimilars | Chemistry | Process Development | Supply Chain
      Biopharma CMO Market Trends

      Biopharma CMO Market Trends

      Continued strong growth in biopharma industry is being driven by biosimilars
      Tim Wright, Editor 06.02.16

    • Biosimilars | Clinical Trials | Formulation Development
      Critical Steps for Biosimilar Assessment

      Critical Steps for Biosimilar Assessment

      Establishing “finger-print like” biosimilarity prior to the clinic
      Fiona Greer, SGS 05.05.16

    • Biosimilars | Clinical Trials | Drug Development
      The Evolving Landscape of Drug Development in China

      The Evolving Landscape of Drug Development in China

      Innovation agenda includes expanded use of biosimulation
      Christine Yuying Gao and Ellen Leinfuss, Certara 05.05.16

    Trending
    • Four Female Leaders Appointed To Cell & Gene CDMO
    • BMS Expands Cell Therapy Manufacturing Capabilities
    • Reed-Lane Facility Virtual Tour
    Breaking News
    • AGC Biologics Expands Cell and Gene Facility in Italy
    • Celonic to Boost Cell & Gene Therapy Production
    • Pharmaron Acquires Biomanufacturing Site in the UK from AbbVie
    • Aptamer Extends Collaboration with AstraZeneca
    • Fujifilm Breaks Ground on Major Expansion of Biologics Facility in Denmark
    View Breaking News >
    CURRENT ISSUE

    March 2021

    • Hygienic Packaging Technology
    • Trends in Solid Oral Dosage Delivery
    • 5 Reasons Paper Has No Place in Contract Manufacturing
    • Injectable Drug Delivery Trends
    • Pharmaceutical Manufacturing Equipment Trends
    • Oral Solids: Market & Technology Trends
    • Nutraceutical Manufacturing: Meeting the Challenges of Today, Planning for Tomorrow
    • 2021 Contract Manufacturing Survey
    • Small Molecule Development Trends
    • Challenges & Opportunities Facing Small & Emerging Biopharma Companies
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Thymoquinone Inhibits Viral Infection in In Vitro Settings, New Study Finds
    IFT Transitions 2021 Annual Event to Digital Experience
    NY Federal Judge Enters Permanent Injunction Against Dietary Supplement Manufacturer
    Coatings World

    Latest Breaking News From Coatings World

    Sherwin-Williams Announces Resignation of President, COO
    Ashland Completes Expansion, Relocation of Viatel Bioresorbable Polymers Manufacturing Facility
    Evonik Receives Sustainability Award from EcoVadis
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Cretex CFO Announces Retirement
    New AI-Based Tool Developed for Coronary Artery Analysis, Intervention Planning
    First Reported Use of Pulse Biosciences' CellFX System
    Contract Pharma

    Latest Breaking News From Contract Pharma

    AGC Biologics Expands Cell and Gene Facility in Italy
    Celonic to Boost Cell & Gene Therapy Production
    Pharmaron Acquires Biomanufacturing Site in the UK from AbbVie
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Ulta Beauty Opens in Herald Square
    Elizabeth Arden Taps Sui He as Global Brand Ambassador
    Natura &Co Outperforms the Global Market in Q4 2020
    Happi

    Latest Breaking News From Happi

    What You're Reading on Happi.com
    Indie Beauty Innovators Wanted
    Cosmetic Chemists Seek Mentors
    Ink World

    Latest Breaking News From Ink World

    Massilly North America Adds Koenig & Bauer MetalStar 3 Metal Decorating Press
    Hydrocarbon Solvents Market to Surpass $8.1 Billion by 2030
    Access Direct Mail Doubles Revenue with SCREEN's Truepress Jet520HD
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Arjobex America welcomes Maggie Naberezny to sales team
    Henkel publishes 30th Sustainability Report
    Avery Dennison Smartrac launches new Circus Pro inlays
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    FPInnovations Develops Biodegradable Mask
    Sani Professional Sanitizing and Disinfecting Products Approved by EPA
    Autefa Solutions Offers Fully Automated Line for Protective Mask Production
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Colfax Decides to Divide Its Businesses
    Stryker Corp.'s 2020 Sales Slip 3.6 Percent
    Bioventus Appoints Managing Director, China and Asia Pacific
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Comercial Kywi Improves Customer Service, Front-Store Operations with Zebra Mobile Solution
    Global Smart Glass Market to Register 6.8% CAGR Between 2021-28: Grand View Research
    Global Printed Circuit Board Market Projected to Reach $69.32 Billion by 2027

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login